Abbvie Drug Patent Portfolio

Abbvie owns 68 orange book drugs protected by 490 US patents with Creon having the least patent protection, holding only 1 patent. And Kaletra with maximum patent protection, holding 49 patents. Given below is the list of Abbvie's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11717515 Treatment of migraine 22 Dec, 2041
Active
US11857542 Treatment of migraine 22 Dec, 2041
Active
US12070450 Treatment of migraine 22 Dec, 2041
Active
US11690845 Methods of administering elagolix 27 Aug, 2040
Active
US11542239 Elagolix sodium compositions and processes 23 Jul, 2039
Active
US10610518 Presbyopia treatments 24 Apr, 2039
Active
US11285134 Presbyopia treatments 24 Apr, 2039
Active
US12083227 Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis 20 Aug, 2038
Active
US11690854 Methods of treating heavy menstrual bleeding 19 Apr, 2038
Active
US11564922 Methods of treating crohn's disease and ulcerative colitis 09 Mar, 2038
Active
US11607411 Methods of treating Crohn's disease and ulcerative colitis 09 Mar, 2038
Active
US11246866 Solid pharmaceutical compositions for treating HCV 24 Dec, 2036
Active
US10202393 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US10344036 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof 17 Oct, 2036
Active
US10519164 Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US10550126 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US10597400 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof 17 Oct, 2036
Active
US10730883 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US10981923 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US10981924 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US10995095 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof 17 Oct, 2036
Active
US11186584 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11198697 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11365198 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11512092 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11524964 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11535624 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11535625 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11535626 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11661425 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11680069 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11718627 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11767326 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11773105 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11773106 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11780847 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11780848 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11787815 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11795175 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11976077 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof 17 Oct, 2036
Active
US11993605 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US11993606 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US12077545 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US9951080 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
Active
US9963459 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof 17 Oct, 2036
Active
US10537572 Methods of administering elagolix 01 Sep, 2036
Active
US10682351 Methods of administering elagolix 01 Sep, 2036
Active
US11246866 Solid pharmaceutical compositions for treating HCV 24 Jun, 2036
Active
US9321807 Crystal forms 05 Dec, 2035
Active
USRE48923 Crystal forms 08 Nov, 2035
Active
US9321807 Crystal forms 05 Jun, 2035
Active
USRE48923 Crystal forms 08 May, 2035
Active
US10117836 Tablet formulation for CGRP active compounds 30 Jan, 2035
Active
US11925709 Tablet formulation for CGRP active compounds 30 Jan, 2035
Active
US10105365 Solid antiviral dosage forms 02 Jan, 2035
Active
US9333204 Solid antiviral dosage forms 02 Jan, 2035
Active
US9744170 Solid antiviral dosage forms 02 Jan, 2035
Active
US9492316 Prostamide-containing intraocular implants and methods of use thereof 31 Oct, 2034
Active
US9980974 Prostamide-containing intraocular implants and methods of use thereof 31 Oct, 2034
Active
US10286029 Method for treating HCV 14 Sep, 2034
Active
US11484534 Methods for treating HCV 14 Sep, 2034
Active
US9669974 Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids 11 May, 2034
Active
US10286029 Method for treating HCV 14 Mar, 2034
Active
US11484534 Methods for treating HCV 14 Mar, 2034
Active
US10881659 Methods of treating heavy menstrual bleeding 14 Mar, 2034
Active
US11045470 Methods of treating heavy menstrual bleeding 14 Mar, 2034
Active
US11344551 Methods of treating heavy menstrual bleeding 14 Mar, 2034
Active
US11707464 Methods of treating heavy menstrual bleeding 14 Mar, 2034
Active
US9676525 Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids 07 Feb, 2034
Active
US8912210 Piperidinone carboxamide azaindane CGRP receptor antagonists 23 Dec, 2033
Active
US10201542 Formulations of pyrimidinedione derivative compounds 18 Oct, 2033
Active
US9629841 Formulations of pyrimidinedione derivative compounds 18 Oct, 2033
Active
US10993942 Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor 06 Sep, 2033
Active
US11110087 Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor 06 Sep, 2033
Active
US11413282 Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor 06 Sep, 2033
Active
US11590128 Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor 06 Sep, 2033
Active
US9539251 Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor 06 Sep, 2033
Active
US9708371 Treatments for gastrointestinal disorders 16 Aug, 2033
Active
USRE47221 Tricyclic compounds 16 Aug, 2033
Active
US10188632 Opioid receptor modulator dosage formulations 14 Mar, 2033
Active
US11007179 Opioid receptor modulator dosage formulations 14 Mar, 2033
Active
US11090291 Opioid receptor modulator dosage formulations 14 Mar, 2033
Active
US11160792 Opioid receptor modulator dosage formulations 14 Mar, 2033
Active
US11229627 Opioid receptor modulator dosage formulations 14 Mar, 2033
Active
US11311516 Opioid receptor modulator dosage formulations 14 Mar, 2033
Active
US11484527 Opioid receptor modulator dosage formulations 14 Mar, 2033
Active
US9675587 Opioid receptor modulator dosage formulations 14 Mar, 2033
Active
US9850246 Process for making CGRP receptor antagonists 13 Mar, 2033
Active
US8937150 Anti-viral compounds 18 Nov, 2032
Active
US8466159 Methods for treating HCV 04 Sep, 2032
Active
US8492386 Methods for treating HCV 04 Sep, 2032
Active
US8680106 Methods for treating HCV 04 Sep, 2032
Active
US8685984 Methods for treating HCV 04 Sep, 2032
Active
US8648037 Macrocyclic proline derived HCV serine protease inhibitors 19 Jul, 2032
Active
US8754096 Piperidinone carboxamide azaindane CGRP receptor antagonists 19 Jul, 2032
Active
US8969566 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof 15 Jun, 2032
Active
US9284314 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof 15 Jun, 2032
Active
US9695122 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof 15 Jun, 2032
Active
US8865937 Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide 23 May, 2032
Active
US11369599 Melt-extruded solid dispersions containing an apoptosis-inducing agent 23 May, 2032
Active
US8937150 Anti-viral compounds 18 May, 2032
Active
US10201541 Compositions and methods for treating HCV 17 May, 2032
Active
US10201584 Compositions and methods for treating HCV 17 May, 2032
Active
US8561859 Dispensing device 16 Apr, 2032
Active
US8691938 Anti-viral compounds 13 Apr, 2032
Active
US8722657 Salts and crystalline forms of an apoptosis-inducing agent 29 Jan, 2032
Active
US8648037 Macrocyclic proline derived HCV serine protease inhibitors 19 Jan, 2032
Active
US10730873 Salts and crystalline forms of an apoptosis-inducing agent 21 Nov, 2031
Active
US9499545 Piperidinone carboxamide azaindane CGRP receptor antagonists 10 Nov, 2031
Active
US9833448 Piperidinone carboxamide azaindane CGRP receptor antagonists 10 Nov, 2031
Active
US8748573 Formulations comprising linaclotide 30 Oct, 2031
Active
US8802628 Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration 30 Oct, 2031
Active
US8420596 Macrocyclic hepatitis C serine protease inhibitors 10 Oct, 2031
Active
US8471025 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt 12 Aug, 2031
Active
US10675325 Stable formulations of linaclotide 11 Aug, 2031
Active
US10702576 Stable formulations of linaclotide 11 Aug, 2031
Active
US8629185 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof 15 Jul, 2031
Active
US8546399 Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases 27 Jun, 2031
Active
US8686026 Solid compositions 09 Jun, 2031
Active
US9586978 Anti-viral compounds 06 May, 2031
Active
US8420596 Macrocyclic hepatitis C serine protease inhibitors 10 Apr, 2031
Active
US9044480 Compositions and methods for treating HCV 10 Apr, 2031
Active
US8920392 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions 26 Mar, 2031
Active
US8481598 Stable dosage forms of levomilnacipran 02 Mar, 2031
Active
US8292129 Dispensing device 25 Feb, 2031
Active
US8933030 Treatments for gastrointestinal disorders 17 Feb, 2031
Active
US8247400 Cephem compounds useful for the treatment of bacterial infections 10 Feb, 2031
Active
US8962629 Tricyclic compounds 15 Jan, 2031
Active
US10028937 Anti-viral compounds 10 Dec, 2030
Active
US10039754 Anti-viral compounds 10 Dec, 2030
Active
US9586978 Anti-viral compounds 06 Nov, 2030
Active
US8835455 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt 08 Oct, 2030
Active
US9629861 Compositions and methods for treating bacterial infections using ceftaroline 21 Sep, 2030
Active
US10028937 Anti-viral compounds 10 Jun, 2030
Active
US10039754 Anti-viral compounds 10 Jun, 2030
Active
US9006387 Anti-viral compounds 10 Jun, 2030
Active
US9174982 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases 26 May, 2030
Active
US10500214 Formulations of deoxycholic acid and salts thereof 02 Mar, 2030
Active
US8101593 Formulations of deoxycholic acid and salts thereof 02 Mar, 2030
Active
US8367649 Formulations of deoxycholic acid and salts thereof 02 Mar, 2030
Active
US8653058 Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits 02 Mar, 2030
Active
US9198871 Delayed release pancreatin compositions 07 Feb, 2030
Active
US8058291 Methods and compositions for the treatment of CNS-related conditions 05 Dec, 2029
Active
US10449173 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions 06 Nov, 2029
Active
US9259388 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions 06 Nov, 2029
Active
US8039009 Modified release formulations of memantine oral dosage forms 24 Sep, 2029
Active
US7994220 Milnacipran for the long-term treatment of fibromyalgia syndrome 19 Sep, 2029
Active
US7737142 (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists 17 Sep, 2029
Active
US8642538 Macrocyclic hepatitis C serine protease inhibitors 10 Sep, 2029
Active
US7842714 Ketorolac tromethamine compositions for treating ocular pain 15 Aug, 2029
Active
USRE47350 Pharmaceutical formulations containing dopamine receptor ligands 16 Jul, 2029
Active
USRE49110 Pharmaceutical formulations containing dopamine receptor ligands 16 Jul, 2029
Active
USRE49302 Pharmaceutical formulations containing dopamine receptor ligands 16 Jul, 2029
Active
US7419983 Gonadotropin-releasing hormone receptor antagonists and methods related thereto 06 Jul, 2029
Active
US7741356 Compounds as opioid receptor modulators 27 May, 2029
Active
US8188104 Anti-infective agents and uses thereof 17 May, 2029
Active
US7799336 Hypotensive lipid-containing biodegradable intraocular implants and related methods 24 Apr, 2029
Active
US8039009 Modified release formulations of memantine oral dosage forms 24 Mar, 2029
Active
US7943621 Salts of piperazine compounds as D3/D2 antagonists 16 Dec, 2028
Active
US9139536 Anti-infective agents and uses thereof 09 Nov, 2028
Active
US11459305 Processes for the preparation of uracil derivatives 07 Nov, 2028
Active
US8501238 Anti-infective agents and uses thereof 17 Sep, 2028
Active
US8691860 Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid 07 Jul, 2028
Active
US9115091 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid 07 Jul, 2028
Active
US9364489 Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid 07 Jul, 2028
Active
US9789125 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid 07 Jul, 2028
Active
US8025899 Solid pharmaceutical dosage form 14 Jun, 2028
Active
US8217083 Mesalamine suppository 06 Jun, 2028
Active
US8436051 Mesalamine suppository 06 Jun, 2028
Active
US6900175 Methods of administering dalbavancin for treatment of bacterial infections 23 May, 2028
Active
US8242294 Synthetic bile acid compositions and methods 16 May, 2028
Active
US8377952 Solid pharmaceutical dosage formulation 22 Apr, 2028
Active
US8512717 Compositions for delivery of therapeutics into the eyes and methods for making and using same 07 Mar, 2028
Active
US9192571 Ketorolac tromethamine compositions for treating or preventing ocular pain 07 Mar, 2028
Active
US8461140 Synthetic bile acid compositions and methods 21 Feb, 2028
Active
US8546367 Synthetic bile acid compositions and methods 21 Feb, 2028
Active
US8883770 Synthetic bile acid compositions and methods 21 Feb, 2028
Active
US9522155 Synthetic bile acid compositions and methods 21 Feb, 2028
Active
US9636349 Synthetic bile acid compositions and methods 21 Feb, 2028
Active
US9949986 Synthetic bile acid compositions and methods 21 Feb, 2028
Active
US8664215 Ocular allergy treatments with alcaftadine 23 Dec, 2027
Active
US8025899 Solid pharmaceutical dosage form 14 Dec, 2027
Active
US7622130 Methods and compositions for the non-surgical removal of fat 10 Dec, 2027
Active
US7754230 Methods and related compositions for reduction of fat 10 Dec, 2027
Active
US8008338 Ketorolac tromethamine compositions for treating or preventing ocular pain 24 Nov, 2027
Active
US8377952 Solid pharmaceutical dosage formulation 22 Oct, 2027
Active
US7838552 Compositions comprising nebivolol 04 Oct, 2027
Active
US7851504 Enhanced bimatoprost ophthalmic solution 13 Jun, 2027
Active
US8008338 Ketorolac tromethamine compositions for treating or preventing ocular pain 24 May, 2027
Active
US8206737 Hypotensive lipid-containing biodegradable intraocular implants and related methods 07 Apr, 2027
Active
US10617695 Ophthalmic compositions containing alcaftadine 19 Mar, 2027
Active
US8470347 Self-emulsifying active substance formulation and use of this formulation 17 Mar, 2027
Active
US10441543 Processes for making cyclic lipid implants for intraocular use 19 Dec, 2026
Active
US9149428 Processes for making cyclic lipid implants for intraocular use 19 Dec, 2026
Active
US7612087 Heterocyclic compounds as inhibitors of beta-lactamases 12 Nov, 2026
Active
US8470347 Self-emulsifying active substance formulation and use of this formulation 17 Sep, 2026
Active
US7304036 Methods and compositions for the treatment of gastrointestinal disorders 30 Aug, 2026
Active
US7803838 Compositions comprising nebivolol 29 Aug, 2026
Active
US8168209 Method and composition for administering an NMDA receptor antagonist to a subject 22 May, 2026
Active
US8173708 Method and composition for administering an NMDA receptor antagonist to a subject 22 May, 2026
Active
US8283379 Methods and compositions for the treatment of CNS-related conditions 22 May, 2026
Active
US8329752 Composition for administering an NMDA receptor antagonist to a subject 22 May, 2026
Active
US8362085 Method for administering an NMDA receptor antagonist to a subject 22 May, 2026
Active
US8598233 Method for administering an NMDA receptor antagonist to a subject 22 May, 2026
Active
USRE43879 Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug 11 Jan, 2026
Active
US7112592 Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents 07 Jan, 2026
Active
US8168209 Method and composition for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
Active
US8173708 Method and composition for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
Active
US8283379 Methods and compositions for the treatment of CNS-related conditions 22 Nov, 2025
Active
US8329752 Composition for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
Active
US8362085 Method for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
Active
US8598233 Method for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
Active
US8293794 Methods and compositions for the treatment of CNS-related conditions 22 Nov, 2025
Active
US8338485 Compositions for the treatment of CNS-related conditions 22 Nov, 2025
Active
US8338486 Methods for the treatment of CNS-related conditions 22 Nov, 2025
Active
US8580858 Compositions for the treatment of CNS-related conditions 22 Nov, 2025
Active
US8298556 Methods and related compositions for the non-surgical removal of fat 03 Aug, 2025
Active
US8309613 Solid pharmaceutical dosage form 24 Jun, 2025
Active
US8278353 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US8299118 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US8309605 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US8338479 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US8524777 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US8586630 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US8772338 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US8933120 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US8933127 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US9155716 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US9241918 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
Active
US10213415 Compounds as opioid receptor modulators 14 Mar, 2025
Active
US7786158 Compounds as opioid receptor modulators 14 Mar, 2025
Active
US8344011 Compounds as opioid receptor modulators 14 Mar, 2025
Active
US8609709 Compounds as opioid receptor modulators 14 Mar, 2025
Active
US8772325 Compounds as opioid receptor modulators 14 Mar, 2025
Active
US9205076 Compounds as opioid receptor modulators 14 Mar, 2025
Active
US9700542 Compounds as opioid receptor modulators 14 Mar, 2025
Active
US8268349 Solid pharmaceutical dosage form 25 Feb, 2025
Active
US8399015 Solid pharmaceutical dosage form 25 Feb, 2025
Active
US8691878 Solid pharmaceutical dosage form 25 Feb, 2025
Active
US8673341 Intraocular pressure reduction with intracameral bimatoprost implants 19 Feb, 2025
Active
US8846066 Methods and related compositions for reduction of fat and skin tightening 08 Feb, 2025
Active
US7259186 Salts of fenofibric acid and pharmaceutical formulations thereof 07 Jan, 2025
Active
US8309613 Solid pharmaceutical dosage form 24 Dec, 2024
Active
US8207215 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 Nov, 2024
Active
US8377982 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 Nov, 2024
Active
US8541463 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 Nov, 2024
Active
US7056927 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 10 Sep, 2024 Expired
US8629111 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024 Expired
US8633162 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024 Expired
US8642556 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024 Expired
US8648048 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024 Expired
US8685930 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024 Expired
US9248191 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024 Expired
US8268349 Solid pharmaceutical dosage form 25 Aug, 2024 Expired
US8399015 Solid pharmaceutical dosage form 25 Aug, 2024 Expired
US8691878 Solid pharmaceutical dosage form 25 Aug, 2024 Expired
US8992952 Compositions for delivery of therapeutics into the eyes and methods for making and using same 05 Aug, 2024 Expired
US7176211 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 06 Jul, 2024 Expired
US8207215 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024 Expired
US8377982 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024 Expired
US8541463 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024 Expired
US8648107 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024 Expired
US8906950 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024 Expired
US8946281 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024 Expired
US9216127 Burial vault and method for customizing a burial vault 28 May, 2024 Expired
US9216167 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024 Expired
US7351404 Method of enhancing hair growth 25 May, 2024 Expired
US8101161 Method of enhancing hair growth 25 May, 2024 Expired
US10398707 Hypotensive lipid-containing biodegradable intraocular implants and related implants 30 Apr, 2024 Expired
US8858961 Compositions containing alpha-2-adrenergic agonist components 02 Mar, 2024 Expired
US7371727 Methods and compositions for the treatment of gastrointestinal disorders 28 Jan, 2024 Expired
US7704947 Methods and compositions for the treatment of gastrointestinal disorders 28 Jan, 2024 Expired
US7745409 Methods and compositions for the treatment of gastrointestinal disorders 28 Jan, 2024 Expired
US8080526 Methods and compositions for the treatment of gastrointestinal disorders 28 Jan, 2024 Expired
US8110553 Methods and compositions for the treatment of gastrointestinal disorders 28 Jan, 2024 Expired
US7115564 Stable pharmaceutical compositions of dalbavancin and methods of administration 14 Nov, 2023 Expired
US7119061 Dalbavancin compositions for treatment of bacterial infections 14 Nov, 2023 Expired
US8143212 Dalbavancin compositions for treatment of bacterial infections 14 Nov, 2023 Expired
US6899717 Methods and apparatus for delivery of ocular implants 01 Nov, 2023 Expired
US8858961 Compositions containing alpha-2-adrenergic agonist components 02 Sep, 2023 Expired
US8038988 Method of enhancing hair growth 25 Aug, 2023 Expired
US8263054 Method of enhancing hair growth 25 Aug, 2023 Expired
US7276249 Nanoparticulate fibrate formulations 21 Feb, 2023 Expired
US7320802 Methods of treatment using nanoparticulate fenofibrate compositions 21 Feb, 2023 Expired
US6916941 Crystalline composition containing escitalopram 12 Feb, 2023 Expired
US7420069 Crystalline composition containing escitalopram 12 Feb, 2023 Expired
US7323463 Combination of brimonidine and timolol for topical ophthalmic use 19 Jan, 2023 Expired
US8632760 Method of enhancing hair growth 15 Jan, 2023 Expired
US8758733 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists 15 Jan, 2023 Expired
US8926953 Method of enhancing hair growth 15 Jan, 2023 Expired
US8986715 Method of enhancing hair growth 15 Jan, 2023 Expired
US9216183 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists 15 Jan, 2023 Expired
US9226931 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists 15 Jan, 2023 Expired
US6602911 Methods of treating fibromyalgia 14 Jan, 2023 Expired
US10076526 Ocular implant made by a double extrusion process 09 Jan, 2023 Expired
US10702539 Ocular implant made by a double extrusion process 09 Jan, 2023 Expired
US8034366 Ocular implant made by a double extrusion process 09 Jan, 2023 Expired
US8034370 Ocular implant made by a double extrusion process 09 Jan, 2023 Expired
US8506987 Ocular implant made by a double extrusion process 09 Jan, 2023 Expired
US9192511 Ocular implant made by a double extrusion process 09 Jan, 2023 Expired
US7834020 Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride 05 Dec, 2022 Expired
US8193195 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride 05 Dec, 2022 Expired
US8236804 Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride 05 Dec, 2022 Expired
US8673921 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride 05 Dec, 2022 Expired
US6916941 Crystalline composition containing escitalopram 12 Aug, 2022 Expired
US7420069 Crystalline composition containing escitalopram 12 Aug, 2022 Expired
US7834020 Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride 05 Jun, 2022 Expired
US8193195 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride 05 Jun, 2022 Expired
US8236804 Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride 05 Jun, 2022 Expired
US8673921 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride 05 Jun, 2022 Expired
US6911214 Flavoring systems for pharmaceutical compositions and methods of making such compositions 28 May, 2022 Expired
US7030149 Combination of brimonidine timolol for topical ophthalmic use 19 Apr, 2022 Expired
US7320976 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022 Expired
US7642258 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022 Expired
US8133890 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022 Expired
US8354409 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022 Expired
US8748425 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022 Expired
US9474751 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022 Expired
US9770453 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022 Expired
US9907801 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022 Expired
US9907802 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022 Expired
US6641834 Compositions containing alpha-2-adrenergic agonist components 28 Jan, 2022 Expired
US6673337 Compositions containing alpha-2-adrenergic agonist components 26 Jan, 2022 Expired
US7388029 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins 21 Jan, 2022 Expired
US6627210 Compositions containing α-2-adrenergic agonist components 18 Jan, 2022 Expired
US6562873 Compositions containing therapeutically active components having enhanced solubility 10 Jan, 2022 Expired
US9295641 Compositions containing alpha-2-adrenergic agonist components 10 Jan, 2022 Expired
US9687443 Compositions containing alpha-2-adrenergic agonist components 10 Jan, 2022 Expired
US6906055 Phosphonocephem compound 15 Dec, 2021 Expired
US7419973 Phosphonocephem compound 15 Dec, 2021 Expired
US6911214 Flavoring systems for pharmaceutical compositions and methods of making such compositions 28 Nov, 2021 Expired
US8501219 Flavoring systems for pharmaceutical compositions and methods of making such compositions 28 Nov, 2021 Expired
US7767223 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use 28 Nov, 2021 Expired
US6893662 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures 15 Nov, 2021 Expired
US8580302 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures 15 Nov, 2021 Expired
US9089492 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures 15 Nov, 2021 Expired
US6992110 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain 05 Nov, 2021 Expired
US7888342 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain 05 Nov, 2021 Expired
US6641834 Compositions containing alpha-2-adrenergic agonist components 28 Jul, 2021 Expired
US6673337 Compositions containing alpha-2-adrenergic agonist components 26 Jul, 2021 Expired
US8178554 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents 24 Jul, 2021 Expired
US6627210 Compositions containing α-2-adrenergic agonist components 18 Jul, 2021 Expired
US10307368 Compositions containing alpha-2-adrenergic agonist components 10 Jul, 2021 Expired
US6562873 Compositions containing therapeutically active components having enhanced solubility 10 Jul, 2021 Expired
US9295641 Compositions containing alpha-2-adrenergic agonist components 10 Jul, 2021 Expired
US9687443 Compositions containing alpha-2-adrenergic agonist components 10 Jul, 2021 Expired
US7364752 Solid dispersion pharamaceutical formulations 10 May, 2021 Expired
US7179815 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 07 Mar, 2021 Expired
US8541466 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins 31 Jan, 2021 Expired
US8906962 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins 31 Jan, 2021 Expired
US9579270 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins 31 Jan, 2021 Expired
US6872728 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 25 Jan, 2021 Expired
US7462625 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 25 Jan, 2021 Expired
US7141593 Pharmaceutical formulations 22 Nov, 2020 Expired
US7432294 Pharmaceutical formulations 22 Nov, 2020 Expired
US7364752 Solid dispersion pharamaceutical formulations 10 Nov, 2020 Expired
US7033605 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor 20 Oct, 2020 Expired
US6726918 Methods for treating inflammation-mediated conditions of the eye 20 Oct, 2020 Expired
US8043628 Methods for reducing edema 20 Oct, 2020 Expired
US8063031 Implants and methods for treating inflammation-mediated conditions of the eye 20 Oct, 2020 Expired
US8088407 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor 20 Oct, 2020 Expired
US9012437 Implants and methods for treating inflammation-mediated conditions of the eye 20 Oct, 2020 Expired
US9283178 Methods for treating edema in the eye and intraocular implants for use therefor 20 Oct, 2020 Expired
US9592242 Methods for treating edema in the eye and intraocular implants for use therefor 20 Oct, 2020 Expired
US9775849 Implants and methods for treating inflammation-mediated conditions of the eye 20 Oct, 2020 Expired
US6375986 Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate 21 Sep, 2020 Expired
US7141593 Pharmaceutical formulations 22 May, 2020 Expired
US7432294 Pharmaceutical formulations 22 May, 2020 Expired
US10272061 Compositions and methods for unoccluded transdermal oxybutynin therapy 26 Apr, 2020 Expired
US7029694 Compositions and methods for transdermal oxybutynin therapy 26 Apr, 2020 Expired
US7179483 Compositions and methods for transdermal oxybutynin therapy 26 Apr, 2020 Expired
US8241662 Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy 26 Apr, 2020 Expired
US6743441 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy 26 Apr, 2020 Expired
US7081249 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy 26 Apr, 2020 Expired
US7081250 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy 26 Apr, 2020 Expired
US7081251 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy 26 Apr, 2020 Expired
US7081252 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy 26 Apr, 2020 Expired
US6649180 Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups 13 Apr, 2020 Expired
US6333045 Aqueous liquid pharmaceutical composition comprised of gatifloxacin 20 Feb, 2020 Expired
US6051567 Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol 02 Feb, 2020 Expired
US6265392 Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol 02 Feb, 2020 Expired
US6274169 Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol 02 Feb, 2020 Expired
US7148359 Polymorph of a pharmaceutical 19 Jan, 2020 Expired
US6333045 Aqueous liquid pharmaceutical composition comprised of gatifloxacin 20 Aug, 2019 Expired
US6051567 Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol 02 Aug, 2019 Expired
US6265392 Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol 02 Aug, 2019 Expired
US6274169 Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol 02 Aug, 2019 Expired
US7148359 Polymorph of a pharmaceutical 19 Jul, 2019 Expired
US6419953 Controlled release formulation of divalproex sodium 18 Jun, 2019 Expired
US6511678 Controlled release formulation of divalproex sodium 18 Jun, 2019 Expired
US6528090 Controlled release formulation of divalproex sodium 18 Jun, 2019 Expired
US6528091 Controlled release formulation of divalproex sodium 18 Jun, 2019 Expired
US6713086 Controlled release formulation of divalproex sodium 18 Jun, 2019 Expired
US6720004 Controlled release formulation of divalproex sodium 18 Jun, 2019 Expired
US6419953 Controlled release formulation of divalproex sodium 18 Dec, 2018 Expired
US6511678 Controlled release formulation of divalproex sodium 18 Dec, 2018 Expired
US6528090 Controlled release formulation of divalproex sodium 18 Dec, 2018 Expired
US6528091 Controlled release formulation of divalproex sodium 18 Dec, 2018 Expired
US6713086 Controlled release formulation of divalproex sodium 18 Dec, 2018 Expired
US6720004 Controlled release formulation of divalproex sodium 18 Dec, 2018 Expired
US6417175 Phosphonocephem derivatives, process for the preparation of the same, and use thereof 17 Dec, 2018 Expired
US6136799 Cosolvent formulations 08 Oct, 2018 Expired
US6361758 Cosolvent formulations 08 Oct, 2018 Expired
US6074668 Container for an inhalation anesthetic 09 Jul, 2018 Expired
US6232333 Pharmaceutical composition 07 May, 2018 Expired
US6458818 Pharmaceutical composition 07 May, 2018 Expired
US6521651 Pharmaceutical composition 07 May, 2018 Expired
US6136799 Cosolvent formulations 08 Apr, 2018 Expired
US6361758 Cosolvent formulations 08 Apr, 2018 Expired
US6469035 Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid 15 Mar, 2018 Expired
US6074670 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it 09 Jan, 2018 Expired
US6277405 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it 09 Jan, 2018 Expired
US6589552 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it 09 Jan, 2018 Expired
US6652881 Fenofibrate pharmaceutical composition having high bioavailability 09 Jan, 2018 Expired
US7037529 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it 09 Jan, 2018 Expired
US7041319 Fenofibrate pharmaceutical composition having high bioavailabilty 09 Jan, 2018 Expired
US6074668 Container for an inhalation anesthetic 09 Jan, 2018 Expired
US6232333 Pharmaceutical composition 07 Nov, 2017 Expired
US6458818 Pharmaceutical composition 07 Nov, 2017 Expired
US6521651 Pharmaceutical composition 07 Nov, 2017 Expired
US5990176 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jul, 2017 Expired
US6288127 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jul, 2017 Expired
US6444859 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jul, 2017 Expired
US6551616 Extended release formulations of erythromycin derivatives 15 Jul, 2017 Expired
US6348216 Ibuprofen and narcotic analgesic compositions 10 Jun, 2017 Expired
US6599531 Method of making ibuprofen and narcotic analgesic compositions 10 Jun, 2017 Expired
US6080428 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 27 May, 2017 Expired
US6010718 Extended release formulations of erythromycin derivatives 11 Apr, 2017 Expired
US5990176 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jan, 2017 Expired
US6288127 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jan, 2017 Expired
US6444859 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jan, 2017 Expired
US6037157 Method for improving pharmacokinetics 26 Dec, 2016 Expired
US6703403 Method for improving pharmacokinetics 26 Dec, 2016 Expired
US5863560 Compositions and methods for topical application of therapeutic agents 11 Sep, 2016 Expired
US6060085 Compositions and methods for topical application of therapeutic agents 11 Sep, 2016 Expired
US6620435 Compositions for topical application of therapeutic agents 11 Sep, 2016 Expired
US6106864 Pharmaceutical formulations containing darifenacin 21 Aug, 2016 Expired
US6284767 Retroviral protease inhibiting compounds 15 Aug, 2016 Expired
US6037157 Method for improving pharmacokinetics 26 Jun, 2016 Expired
US6703403 Method for improving pharmacokinetics 26 Jun, 2016 Expired
US5914332 Retroviral protease inhibiting compounds 13 Jun, 2016 Expired
US5880283 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same 05 Jun, 2016 Expired
US6284767 Retroviral protease inhibiting compounds 15 Feb, 2016 Expired
US5597815 Prevention of hyperphosphatemia in kidney disorder patients 13 Jan, 2016 Expired
US5914332 Retroviral protease inhibiting compounds 13 Dec, 2015 Expired
US5880283 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same 05 Dec, 2015 Expired
US5061703 Adamantane derivatives in the prevention and treatment of cerebral ischemia 11 Oct, 2015 Expired
US5597815 Prevention of hyperphosphatemia in kidney disorder patients 13 Jul, 2015 Expired
US5744496 Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors 28 Apr, 2015 Expired
US5601839 Triacetin as a penetration enhancer for transdermal delivery of a basic drug 26 Apr, 2015 Expired
US5834010 Triacetin as a penetration enhancer for transdermal delivery of a basic drug 26 Apr, 2015 Expired
US5061703 Adamantane derivatives in the prevention and treatment of cerebral ischemia 11 Apr, 2015 Expired
US5096890 Pyrrolidine derivatives 13 Mar, 2015 Expired
US5721244 Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs 24 Feb, 2015 Expired
US5648497 Retroviral protease inhibiting compounds 15 Jan, 2015 Expired
US5532241 Piperidines and piperazines 29 Sep, 2014 Expired
US5688819 Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents 19 Aug, 2014 Expired
US5656650 Angiotensin II receptor blocking compositions 12 Aug, 2014 Expired
US5484801 Pharmaceutical composition for inhibiting HIV protease 28 Jul, 2014 Expired
US5648497 Retroviral protease inhibiting compounds 15 Jul, 2014 Expired
US5587497 19-nor-vitamin D compounds 24 Jun, 2014 Expired
US7189761 Nitric oxide donor composition and method for treatment of anal disorders 27 May, 2014 Expired
US5886036 Retroviral protease inhibiting compounds 19 May, 2014 Expired
US5474979 Nonirritating emulsions for sensitive tissue 17 May, 2014 Expired
US5948436 Pharmaceutical composition 13 Mar, 2014 Expired
US5541206 Retroviral protease inhibiting compounds 30 Jan, 2014 Expired
US5635523 Retroviral protease inhibiting compounds 30 Jan, 2014 Expired
US5674882 Retroviral protease inhibiting compounds 30 Jan, 2014 Expired
US5484801 Pharmaceutical composition for inhibiting HIV protease 28 Jan, 2014 Expired
US5587497 19-nor-vitamin D compounds 24 Dec, 2013 Expired
US5468743 Imidazo[2,1-b]benzazepine derivatives, compositions and method of use 21 Nov, 2013 Expired
US5886036 Retroviral protease inhibiting compounds 19 Nov, 2013 Expired
US6129930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night 20 Sep, 2013 Expired
US6406715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles 20 Sep, 2013 Expired
US6676967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia 20 Sep, 2013 Expired
US6746691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics 20 Sep, 2013 Expired
US6818229 Intermediate release nicotinic acid compositions for treating hyperlipidemia 20 Sep, 2013 Expired
US7011848 Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor 20 Sep, 2013 Expired
US7998506 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 20 Sep, 2013 Expired
US5948436 Pharmaceutical composition 13 Sep, 2013 Expired
US5541170 Orally administrable pharmaceutical compositions 30 Jul, 2013 Expired
US5541171 Orally administrable pharmaceutical composition 30 Jul, 2013 Expired
US5541206 Retroviral protease inhibiting compounds 30 Jul, 2013 Expired
US5635523 Retroviral protease inhibiting compounds 30 Jul, 2013 Expired
US5674882 Retroviral protease inhibiting compounds 30 Jul, 2013 Expired
US5424078 Aqueous ophthalmic formulations and methods for preserving same 13 Dec, 2012 Expired
US8017655 Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents 27 Nov, 2012 Expired
US5246925 19-nor-vitamin D compounds for use in treating hyperparathyroidism 17 Oct, 2012 Expired
US5453510 Neuromuscular blocking agents 26 Sep, 2012 Expired
US6403649 Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents 21 Sep, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Abbvie.

Activity Date Patent Number
Patent litigations
Email Notification 19 Jul, 2024 US11369599
Mail O.P. Petition Decision 19 Jul, 2024 US11369599
Mail-Petition Decision - Denied 16 Jul, 2024 US11369599
Mail-Petition Decision - Granted 16 Jul, 2024 US11369599
Petition Decision - Denied 15 Jul, 2024 US11369599
O.P. Petition Decision 15 Jul, 2024 US11369599
Petition Decision - Granted 15 Jul, 2024 US11369599
Payment of Maintenance Fee, 12th Year, Large Entity 11 Jul, 2024 US8367649
Post Issue Communication - Certificate of Correction 08 Jul, 2024 US11542239
Post Issue Communication - Certificate of Correction 08 Jul, 2024 US11542239
Expire Patent 08 Jul, 2024 US8193195 (Litigated)
Mail Certificate of Correction Memo 05 Jul, 2024 US11542239
Mail Certificate of Correction Memo 05 Jul, 2024 US11542239
Certificate of Correction Memo 02 Jul, 2024 US11542239
Certificate of Correction Memo 02 Jul, 2024 US11542239


Abbvie's Drug Patent Litigations

Abbvie's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 02, 2006, against patent number US8008338. The petitioner , challenged the validity of this patent, with Christopher A. Muller et al as the respondent. Click below to track the latest information on how companies are challenging Abbvie's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11110087 October, 2022 Final Written Decision - Appealed
(16 Apr, 2024)
Genentech, Inc. et al. Dr. Reddy's Laboratories, Inc. et al.
US10993942 February, 2022 Final Written Decision - Appealed
(10 Aug, 2023)
Genentech, Inc. et al. Dr. Reddy's Laboratories, Inc. et al.
US8648048 January, 2017 Terminated
(27 Sep, 2019)
Allergan, Inc. Teva Pharmaceuticals USA, Inc.
US9248191 June, 2016 Terminated
(27 Sep, 2019)
Allergan, Inc. Mylan Pharmaceuticals Inc. et al.
US8642556 June, 2016 FWD Entered
(27 Sep, 2019)
Allergan, Inc. Mylan Pharmaceuticals Inc.
US8685930 June, 2016 Terminated
(27 Sep, 2019)
Allergan, Inc. Mylan Pharmaceuticals Inc. et al.
US8629111 June, 2016 Terminated
(27 Sep, 2019)
Allergan, Inc. Mylan Pharmaceuticals Inc. et al.
US8633162 June, 2016 FWD Entered
(27 Sep, 2019)
Allergan, Inc. Mylan Pharmaceuticals Inc.
US8629111 January, 2017 Terminated
(27 Sep, 2019)
Allergan, Inc. Akorn, Inc.
US8648048 June, 2016 Terminated
(27 Sep, 2019)
Allergan, Inc. Mylan Pharmaceuticals Inc. et al.
US8685930 January, 2017 Terminated
(27 Sep, 2019)
Allergan, Inc. Akorn, Inc.
US9248191 January, 2017 Terminated
(27 Sep, 2019)
Allergan, Inc. Teva Pharmaceuticals USA, Inc.
US8633162 January, 2017 FWD Entered
(27 Sep, 2019)
Allergan, Inc. Teva Pharmaceuticals USA, Inc.
US8642556 January, 2017 FWD Entered
(27 Sep, 2019)
Allergan, Inc. Akorn, Inc.
US8673921 January, 2018 Terminated-Denied
(23 Jul, 2018)
Merck Patentgesellschaft Mit Beschrankter Haftung Argentum Pharmaceuticals LLC
US6649180 November, 2016 Terminated-Settled
(19 Dec, 2017)
Qualicaps Co., Ltd. Mylan Pharmaceuticals Inc.
US8642556 January, 2017 Terminated-Settled
(06 Sep, 2017)
Allergan, Inc. Famy Care Limited
US8629111 January, 2017 Terminated-Settled
(06 Sep, 2017)
Allergan, Inc. Famy Care Limited
US8648048 January, 2017 Terminated-Settled
(06 Sep, 2017)
Allergan, Inc. Famy Care Limited
US8633162 January, 2017 Terminated-Settled
(06 Sep, 2017)
Allergan, Inc. Famy Care Limited
US8685930 January, 2017 Terminated-Settled
(06 Sep, 2017)
Allergan, Inc. Famy Care Limited
US9248191 January, 2017 Terminated-Settled
(06 Sep, 2017)
Allergan, Inc. Famy Care Limited
US8629111 January, 2017 Terminated
(31 Mar, 2017)
Allergan, Inc. Teva Pharmaceuticals USA, Inc.
US9248191 January, 2017 Terminated
(31 Mar, 2017)
Allergan, Inc. Akorn, Inc.
US8648048 January, 2017 Terminated
(31 Mar, 2017)
Allergan, Inc. Akorn, Inc.
US8642556 January, 2017 FWD Entered
(31 Mar, 2017)
Allergan, Inc. Teva Pharmaceuticals USA, Inc.
US8685930 January, 2017 Terminated
(31 Mar, 2017)
Allergan, Inc. Teva Pharmaceuticals USA, Inc.
US8633162 January, 2017 FWD Entered
(31 Mar, 2017)
Allergan, Inc. Akorn, Inc.
US8629111 June, 2016 Terminated-Settled
(08 Dec, 2016)
Allergan, Inc. Argentum Pharmaceuticals LLC
US8648048 June, 2015 Terminated-Denied
(16 Dec, 2015)
Allergan, Inc. Apotex Corp.
US8685930 June, 2015 Terminated-Denied
(16 Dec, 2015)
Allergan, Inc. Apotex Corp.
US8642556 June, 2015 Terminated-Denied
(16 Dec, 2015)
Allergan, Inc. Apotex Corp.
US8633162 June, 2015 Terminated-Denied
(16 Dec, 2015)
Allergan, Inc. Apotex Corp.
US8629111 June, 2015 Terminated-Denied
(16 Dec, 2015)
Allergan, Inc. Apotex Corp.
US7030149 March, 2015 Terminated-Denied
(21 Sep, 2015)
Allergan Sales, LLC Ferrum Ferro Capital, LLC
US8362085 December, 2014 Terminated-Denied
(15 May, 2015)
Adamas Pharmaceuticals, Inc. Ranbaxy, Inc.
US8008338 November, 2010 Decision
(29 Mar, 2011)
Christopher A. Muller et al
US8470347 August, 2009 Decision
(27 May, 2010)
Gunther Berndl et al
US7851504 January, 2009 Decision
(10 May, 2010)
Chin-Ming Chang et al
US8008338 August, 2006 Decision
(21 Dec, 2006)
Christopher A. Muller et al


Abbvie Drug Patents' Oppositions Filed in EPO

Abbvie drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 11, 2005, by Egis Gyogyszergyar Rt.. This opposition was filed on patent number EP02750846A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP19729883A Dec, 2022 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP17165207A May, 2021 Generics (U.K.) Limited Granted and Under Opposition
EP17182561A Nov, 2019 Lederer & Keller Patentanwälte Partnerschaft mbB Patent maintained as amended
EP03789744A Jul, 2019 Fresenius Kabi Deutschland GmbH Granted and Under Opposition
EP14774006A May, 2019 Sandoz AG Opposition rejected
EP15176068A Apr, 2019 Aechter, Bernd Revoked
EP14815668A Oct, 2018 Epping Hermann Fischer Patentanwaltgesellschaft MBH Patent maintained as amended
EP11791401A May, 2018 Generics (U.K.) Limited Revoked
EP10835061A Feb, 2018 Generics (U.K.) Limited Opposition rejected
EP14719977A Jan, 2018 Generics (U.K.) Limited Granted and Under Opposition
EP12753313A Sep, 2017 Hexal AG Revoked
EP11727080A Apr, 2016 KELTIE LLP Patent maintained as amended
EP11727080A Apr, 2016 Ter Meer Steinmeister & Partner Patentanwälte mbB Patent maintained as amended
EP05852057A Dec, 2013 Elend, Almut Susanne Revoked
EP10185774A Dec, 2013 Generics [UK] Limited Revoked
EP07017089A Dec, 2013 Generics [UK] Limited Revoked
EP03726234A Oct, 2013 Hexal AG Revoked
EP03726234A Oct, 2013 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Revoked
EP03726234A Oct, 2013 Generics [UK] Limited Revoked
EP03726234A Oct, 2013 Alfred E. Tiefenbacher GmbH & Co. KG Revoked
EP03726234A Oct, 2013 Teva Pharmaceutical Industries LTD. Revoked
EP03726234A Oct, 2013 STADA Arzneimittel AG Revoked
EP10170038A Mar, 2013 Generics [UK] Limited Opposition rejected
EP06749777A Jun, 2011 Merz Pharma GmbH & Co. KGaA Revoked
EP04780382A Jul, 2010 ALCON LABORATORIES, INC. Patent maintained as amended
EP06738208A Feb, 2010 Teva Pharmaceutical Industries Ltd. Patent maintained as amended
EP06738208A Feb, 2010 Ratiopharm GmbH Patent maintained as amended
EP04029282A Oct, 2007 Ratiopharm GmbH Revoked
EP04029282A Oct, 2007 Krka, Tovarna Zdravil, d.d. Revoked
EP04029282A Oct, 2007 Generics [UK] Limited Revoked
EP04029282A Oct, 2007 Actavis Group hf Revoked
EP04029282A Oct, 2007 EGIS Gyógyszergyár Nyrt Revoked
EP04029282A Sep, 2007 Pliva Hrvatska D.O.O. Revoked
EP03723781A Jul, 2007 Abraxis BioScience, Inc. Patent maintained as amended
EP03723781A Jul, 2007 Baxter Healthcare Corporation Patent maintained as amended
EP04029282A Jan, 2007 SANDOZ AG Revoked
EP02750846A Oct, 2005 Egis Gyogyszergyar RT. Revoked


Abbvie's Family Patents

Abbvie drugs have patent protection in a total of 74 countries. It's US patent count contributes only to 27.3% of its total global patent coverage. 15 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Abbvie Drug List

Given below is the complete list of Abbvie's drugs and the patents protecting them.


1. Acular Ls

Acular Ls is protected by 13 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8008338
(Pediatric)
Ketorolac tromethamine compositions for treating or preventing ocular pain 24 Nov, 2027
(3 years from now)
Active
US8008338 Ketorolac tromethamine compositions for treating or preventing ocular pain 24 May, 2027
(2 years from now)
Active
US8207215
(Pediatric)
Ketorolac tromethamine compositions for treating or preventing ocular pain 28 Nov, 2024
(a month from now)
Active
US8377982
(Pediatric)
Ketorolac tromethamine compositions for treating or preventing ocular pain 28 Nov, 2024
(a month from now)
Active
US8541463
(Pediatric)
Ketorolac tromethamine compositions for treating or preventing ocular pain 28 Nov, 2024
(a month from now)
Active
US8207215 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024
(4 months ago)
Expired
US8377982 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024
(4 months ago)
Expired
US8541463 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024
(4 months ago)
Expired
US8648107 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024
(4 months ago)
Expired
US8906950 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024
(4 months ago)
Expired
US8946281 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024
(4 months ago)
Expired
US9216127 Burial vault and method for customizing a burial vault 28 May, 2024
(4 months ago)
Expired
US9216167 Ketorolac tromethamine compositions for treating or preventing ocular pain 28 May, 2024
(4 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acular Ls's drug page


2. Acuvail

Acuvail is protected by 4 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7842714 Ketorolac tromethamine compositions for treating ocular pain 15 Aug, 2029
(4 years from now)
Active
US8512717 Compositions for delivery of therapeutics into the eyes and methods for making and using same 07 Mar, 2028
(3 years from now)
Active
US9192571 Ketorolac tromethamine compositions for treating or preventing ocular pain 07 Mar, 2028
(3 years from now)
Active
US8992952 Compositions for delivery of therapeutics into the eyes and methods for making and using same 05 Aug, 2024
(2 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acuvail's drug page


3. Aczone

Aczone is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5863560 Compositions and methods for topical application of therapeutic agents 11 Sep, 2016
(8 years ago)
Expired
US6060085 Compositions and methods for topical application of therapeutic agents 11 Sep, 2016
(8 years ago)
Expired
US6620435 Compositions for topical application of therapeutic agents 11 Sep, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aczone's drug page


4. Advicor

Advicor is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6469035 Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid 15 Mar, 2018
(6 years ago)
Expired
US6080428 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 27 May, 2017
(7 years ago)
Expired
US6129930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night 20 Sep, 2013
(11 years ago)
Expired
US6406715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles 20 Sep, 2013
(11 years ago)
Expired
US6676967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia 20 Sep, 2013
(11 years ago)
Expired
US6746691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics 20 Sep, 2013
(11 years ago)
Expired
US6818229 Intermediate release nicotinic acid compositions for treating hyperlipidemia 20 Sep, 2013
(11 years ago)
Expired
US7011848 Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor 20 Sep, 2013
(11 years ago)
Expired
US7998506 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 20 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Advicor's drug page


5. Alphagan P

Alphagan P is protected by 16 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8858961
(Pediatric)
Compositions containing alpha-2-adrenergic agonist components 02 Mar, 2024
(7 months ago)
Expired
US8858961 Compositions containing alpha-2-adrenergic agonist components 02 Sep, 2023
(1 year, 1 month ago)
Expired
US6641834
(Pediatric)
Compositions containing alpha-2-adrenergic agonist components 28 Jan, 2022
(2 years ago)
Expired
US6673337
(Pediatric)
Compositions containing alpha-2-adrenergic agonist components 26 Jan, 2022
(2 years ago)
Expired
US6627210
(Pediatric)
Compositions containing α-2-adrenergic agonist components 18 Jan, 2022
(2 years ago)
Expired
US6562873
(Pediatric)
Compositions containing therapeutically active components having enhanced solubility 10 Jan, 2022
(2 years ago)
Expired
US9295641
(Pediatric)
Compositions containing alpha-2-adrenergic agonist components 10 Jan, 2022
(2 years ago)
Expired
US9687443
(Pediatric)
Compositions containing alpha-2-adrenergic agonist components 10 Jan, 2022
(2 years ago)
Expired
US6641834 Compositions containing alpha-2-adrenergic agonist components 28 Jul, 2021
(3 years ago)
Expired
US6673337 Compositions containing alpha-2-adrenergic agonist components 26 Jul, 2021
(3 years ago)
Expired
US6627210 Compositions containing α-2-adrenergic agonist components 18 Jul, 2021
(3 years ago)
Expired
US10307368 Compositions containing alpha-2-adrenergic agonist components 10 Jul, 2021
(3 years ago)
Expired
US6562873 Compositions containing therapeutically active components having enhanced solubility 10 Jul, 2021
(3 years ago)
Expired
US9295641 Compositions containing alpha-2-adrenergic agonist components 10 Jul, 2021
(3 years ago)
Expired
US9687443 Compositions containing alpha-2-adrenergic agonist components 10 Jul, 2021
(3 years ago)
Expired
US5424078
(Pediatric)
Aqueous ophthalmic formulations and methods for preserving same 13 Dec, 2012
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alphagan P's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Asacol Hd

Asacol Hd is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6893662 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures 15 Nov, 2021
(2 years ago)
Expired
US8580302 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures 15 Nov, 2021
(2 years ago)
Expired
US9089492 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures 15 Nov, 2021
(2 years ago)
Expired
US5541170 Orally administrable pharmaceutical compositions 30 Jul, 2013
(11 years ago)
Expired
US5541171 Orally administrable pharmaceutical composition 30 Jul, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Asacol Hd's drug page


7. Avycaz

Avycaz is protected by 8 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8969566 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof 15 Jun, 2032
(7 years from now)
Active
US9284314 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof 15 Jun, 2032
(7 years from now)
Active
US9695122 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof 15 Jun, 2032
(7 years from now)
Active
US8471025 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt 12 Aug, 2031
(6 years from now)
Active
US8835455 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt 08 Oct, 2030
(5 years from now)
Active
US7612087 Heterocyclic compounds as inhibitors of beta-lactamases 12 Nov, 2026
(2 years from now)
Active
US7112592 Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents 07 Jan, 2026
(1 year, 2 months from now)
Active
US8178554 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents 24 Jul, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avycaz's drug page


8. Biaxin Xl

Biaxin Xl is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6551616 Extended release formulations of erythromycin derivatives 15 Jul, 2017
(7 years ago)
Expired
US6010718 Extended release formulations of erythromycin derivatives 11 Apr, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Biaxin Xl's drug page


9. Byvalson

Byvalson is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7838552 Compositions comprising nebivolol 04 Oct, 2027
(2 years from now)
Active
US7803838 Compositions comprising nebivolol 29 Aug, 2026
(1 year, 10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Byvalson's drug page


10. Calcijex

Calcijex is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6051567
(Pediatric)
Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol 02 Feb, 2020
(4 years ago)
Expired
US6265392
(Pediatric)
Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol 02 Feb, 2020
(4 years ago)
Expired
US6274169
(Pediatric)
Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol 02 Feb, 2020
(4 years ago)
Expired
US6051567 Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol 02 Aug, 2019
(5 years ago)
Expired
US6265392 Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol 02 Aug, 2019
(5 years ago)
Expired
US6274169 Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol 02 Aug, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Calcijex's drug page


11. Canasa

Canasa is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8217083 Mesalamine suppository 06 Jun, 2028
(3 years from now)
Active
US8436051 Mesalamine suppository 06 Jun, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Canasa's drug page


12. Combigan

Combigan is protected by 11 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7323463 Combination of brimonidine and timolol for topical ophthalmic use 19 Jan, 2023
(1 year, 8 months ago)
Expired
US7030149 Combination of brimonidine timolol for topical ophthalmic use 19 Apr, 2022
(2 years ago)
Expired
US7320976 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022
(2 years ago)
Expired
US7642258 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022
(2 years ago)
Expired
US8133890 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022
(2 years ago)
Expired
US8354409 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022
(2 years ago)
Expired
US8748425 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022
(2 years ago)
Expired
US9474751 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022
(2 years ago)
Expired
US9770453 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022
(2 years ago)
Expired
US9907801 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022
(2 years ago)
Expired
US9907802 Combination of brimonidine and timolol for topical ophthalmic use 19 Apr, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combigan's drug page


13. Creon

Creon is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9198871 Delayed release pancreatin compositions 07 Feb, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Creon's drug page


14. Dalvance

Dalvance is protected by 4 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6900175 Methods of administering dalbavancin for treatment of bacterial infections 23 May, 2028
(3 years from now)
Active
US7115564 Stable pharmaceutical compositions of dalbavancin and methods of administration 14 Nov, 2023
(10 months ago)
Expired
US7119061 Dalbavancin compositions for treatment of bacterial infections 14 Nov, 2023
(10 months ago)
Expired
US8143212 Dalbavancin compositions for treatment of bacterial infections 14 Nov, 2023
(10 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dalvance's drug page


15. Delzicol

Delzicol is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6649180 Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups 13 Apr, 2020
(4 years ago)
Expired
US5541170 Orally administrable pharmaceutical compositions 30 Jul, 2013
(11 years ago)
Expired
US5541171 Orally administrable pharmaceutical composition 30 Jul, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Delzicol's drug page


16. Depakote Er

Depakote Er is protected by 12 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6419953
(Pediatric)
Controlled release formulation of divalproex sodium 18 Jun, 2019
(5 years ago)
Expired
US6511678
(Pediatric)
Controlled release formulation of divalproex sodium 18 Jun, 2019
(5 years ago)
Expired
US6528090
(Pediatric)
Controlled release formulation of divalproex sodium 18 Jun, 2019
(5 years ago)
Expired
US6528091
(Pediatric)
Controlled release formulation of divalproex sodium 18 Jun, 2019
(5 years ago)
Expired
US6713086
(Pediatric)
Controlled release formulation of divalproex sodium 18 Jun, 2019
(5 years ago)
Expired
US6720004
(Pediatric)
Controlled release formulation of divalproex sodium 18 Jun, 2019
(5 years ago)
Expired
US6419953 Controlled release formulation of divalproex sodium 18 Dec, 2018
(5 years ago)
Expired
US6511678 Controlled release formulation of divalproex sodium 18 Dec, 2018
(5 years ago)
Expired
US6528090 Controlled release formulation of divalproex sodium 18 Dec, 2018
(5 years ago)
Expired
US6528091 Controlled release formulation of divalproex sodium 18 Dec, 2018
(5 years ago)
Expired
US6713086 Controlled release formulation of divalproex sodium 18 Dec, 2018
(5 years ago)
Expired
US6720004 Controlled release formulation of divalproex sodium 18 Dec, 2018
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Depakote Er's drug page


17. Durysta

Durysta is protected by 10 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9492316 Prostamide-containing intraocular implants and methods of use thereof 31 Oct, 2034
(10 years from now)
Active
US9980974 Prostamide-containing intraocular implants and methods of use thereof 31 Oct, 2034
(10 years from now)
Active
US8629185 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof 15 Jul, 2031
(6 years from now)
Active
US7799336 Hypotensive lipid-containing biodegradable intraocular implants and related methods 24 Apr, 2029
(4 years from now)
Active
US8206737 Hypotensive lipid-containing biodegradable intraocular implants and related methods 07 Apr, 2027
(2 years from now)
Active
US10441543 Processes for making cyclic lipid implants for intraocular use 19 Dec, 2026
(2 years from now)
Active
US9149428 Processes for making cyclic lipid implants for intraocular use 19 Dec, 2026
(2 years from now)
Active
US8673341 Intraocular pressure reduction with intracameral bimatoprost implants 19 Feb, 2025
(4 months from now)
Active
US10398707 Hypotensive lipid-containing biodegradable intraocular implants and related implants 30 Apr, 2024
(5 months ago)
Expired
US7033605 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor 20 Oct, 2020
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Durysta's drug page


18. Enablex

Enablex is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6106864 Pharmaceutical formulations containing darifenacin 21 Aug, 2016
(8 years ago)
Expired
US5096890 Pyrrolidine derivatives 13 Mar, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Enablex's drug page


19. Fetzima

Fetzima is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8865937 Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide 23 May, 2032
(7 years from now)
Active
US8481598 Stable dosage forms of levomilnacipran 02 Mar, 2031
(6 years from now)
Active
USRE43879 Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug 11 Jan, 2026
(1 year, 2 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fetzima's drug page


20. Gelnique

Gelnique is protected by 7 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8920392 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions 26 Mar, 2031
(6 years from now)
Active
US10449173 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions 06 Nov, 2029
(5 years from now)
Active
US9259388 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions 06 Nov, 2029
(5 years from now)
Active
US10272061 Compositions and methods for unoccluded transdermal oxybutynin therapy 26 Apr, 2020
(4 years ago)
Expired
US7029694 Compositions and methods for transdermal oxybutynin therapy 26 Apr, 2020
(4 years ago)
Expired
US7179483 Compositions and methods for transdermal oxybutynin therapy 26 Apr, 2020
(4 years ago)
Expired
US8241662 Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy 26 Apr, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gelnique's drug page


21. Kaletra

Kaletra is protected by 49 patents, out of which 38 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8025899
(Pediatric)
Solid pharmaceutical dosage form 14 Jun, 2028
(3 years from now)
Active
US8377952
(Pediatric)
Solid pharmaceutical dosage formulation 22 Apr, 2028
(3 years from now)
Active
US8025899 Solid pharmaceutical dosage form 14 Dec, 2027
(3 years from now)
Active
US8377952 Solid pharmaceutical dosage formulation 22 Oct, 2027
(3 years from now)
Active
US8470347
(Pediatric)
Self-emulsifying active substance formulation and use of this formulation 17 Mar, 2027
(2 years from now)
Active
US8470347 Self-emulsifying active substance formulation and use of this formulation 17 Sep, 2026
(1 year, 11 months from now)
Active
US8309613
(Pediatric)
Solid pharmaceutical dosage form 24 Jun, 2025
(8 months from now)
Active
US8268349
(Pediatric)
Solid pharmaceutical dosage form 25 Feb, 2025
(4 months from now)
Active
US8399015
(Pediatric)
Solid pharmaceutical dosage form 25 Feb, 2025
(4 months from now)
Active
US8691878
(Pediatric)
Solid pharmaceutical dosage form 25 Feb, 2025
(4 months from now)
Active
US8309613 Solid pharmaceutical dosage form 24 Dec, 2024
(2 months from now)
Active
US8268349 Solid pharmaceutical dosage form 25 Aug, 2024
(a month ago)
Expired
US8399015 Solid pharmaceutical dosage form 25 Aug, 2024
(a month ago)
Expired
US8691878 Solid pharmaceutical dosage form 25 Aug, 2024
(a month ago)
Expired
US6911214
(Pediatric)
Flavoring systems for pharmaceutical compositions and methods of making such compositions 28 May, 2022
(2 years ago)
Expired
US6911214 Flavoring systems for pharmaceutical compositions and methods of making such compositions 28 Nov, 2021
(2 years ago)
Expired
US8501219 Flavoring systems for pharmaceutical compositions and methods of making such compositions 28 Nov, 2021
(2 years ago)
Expired
US7364752
(Pediatric)
Solid dispersion pharamaceutical formulations 10 May, 2021
(3 years ago)
Expired
US7141593
(Pediatric)
Pharmaceutical formulations 22 Nov, 2020
(3 years ago)
Expired
US7432294
(Pediatric)
Pharmaceutical formulations 22 Nov, 2020
(3 years ago)
Expired
US7364752 Solid dispersion pharamaceutical formulations 10 Nov, 2020
(3 years ago)
Expired
US7141593 Pharmaceutical formulations 22 May, 2020
(4 years ago)
Expired
US7432294 Pharmaceutical formulations 22 May, 2020
(4 years ago)
Expired
US7148359
(Pediatric)
Polymorph of a pharmaceutical 19 Jan, 2020
(4 years ago)
Expired
US7148359 Polymorph of a pharmaceutical 19 Jul, 2019
(5 years ago)
Expired
US6232333
(Pediatric)
Pharmaceutical composition 07 May, 2018
(6 years ago)
Expired
US6458818
(Pediatric)
Pharmaceutical composition 07 May, 2018
(6 years ago)
Expired
US6521651
(Pediatric)
Pharmaceutical composition 07 May, 2018
(6 years ago)
Expired
US6232333 Pharmaceutical composition 07 Nov, 2017
(6 years ago)
Expired
US6458818 Pharmaceutical composition 07 Nov, 2017
(6 years ago)
Expired
US6521651 Pharmaceutical composition 07 Nov, 2017
(6 years ago)
Expired
US6037157
(Pediatric)
Method for improving pharmacokinetics 26 Dec, 2016
(7 years ago)
Expired
US6703403
(Pediatric)
Method for improving pharmacokinetics 26 Dec, 2016
(7 years ago)
Expired
US6284767
(Pediatric)
Retroviral protease inhibiting compounds 15 Aug, 2016
(8 years ago)
Expired
US6037157 Method for improving pharmacokinetics 26 Jun, 2016
(8 years ago)
Expired
US6703403 Method for improving pharmacokinetics 26 Jun, 2016
(8 years ago)
Expired
US5914332
(Pediatric)
Retroviral protease inhibiting compounds 13 Jun, 2016
(8 years ago)
Expired
US6284767 Retroviral protease inhibiting compounds 15 Feb, 2016
(8 years ago)
Expired
US5914332 Retroviral protease inhibiting compounds 13 Dec, 2015
(8 years ago)
Expired
US5648497
(Pediatric)
Retroviral protease inhibiting compounds 15 Jan, 2015
(9 years ago)
Expired
US5484801
(Pediatric)
Pharmaceutical composition for inhibiting HIV protease 28 Jul, 2014
(10 years ago)
Expired
US5648497 Retroviral protease inhibiting compounds 15 Jul, 2014
(10 years ago)
Expired
US5886036
(Pediatric)
Retroviral protease inhibiting compounds 19 May, 2014
(10 years ago)
Expired
US5948436
(Pediatric)
Pharmaceutical composition 13 Mar, 2014
(10 years ago)
Expired
US5541206
(Pediatric)
Retroviral protease inhibiting compounds 30 Jan, 2014
(10 years ago)
Expired
US5484801 Pharmaceutical composition for inhibiting HIV protease 28 Jan, 2014
(10 years ago)
Expired
US5886036 Retroviral protease inhibiting compounds 19 Nov, 2013
(10 years ago)
Expired
US5948436 Pharmaceutical composition 13 Sep, 2013
(11 years ago)
Expired
US5541206 Retroviral protease inhibiting compounds 30 Jul, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kaletra's drug page


22. Kybella

Kybella is protected by 15 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10500214 Formulations of deoxycholic acid and salts thereof 02 Mar, 2030
(5 years from now)
Active
US8101593 Formulations of deoxycholic acid and salts thereof 02 Mar, 2030
(5 years from now)
Active
US8367649 Formulations of deoxycholic acid and salts thereof 02 Mar, 2030
(5 years from now)
Active
US8653058 Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits 02 Mar, 2030
(5 years from now)
Active
US8242294 Synthetic bile acid compositions and methods 16 May, 2028
(3 years from now)
Active
US8461140 Synthetic bile acid compositions and methods 21 Feb, 2028
(3 years from now)
Active
US8546367 Synthetic bile acid compositions and methods 21 Feb, 2028
(3 years from now)
Active
US8883770 Synthetic bile acid compositions and methods 21 Feb, 2028
(3 years from now)
Active
US9522155 Synthetic bile acid compositions and methods 21 Feb, 2028
(3 years from now)
Active
US9636349 Synthetic bile acid compositions and methods 21 Feb, 2028
(3 years from now)
Active
US9949986 Synthetic bile acid compositions and methods 21 Feb, 2028
(3 years from now)
Active
US7622130 Methods and compositions for the non-surgical removal of fat 10 Dec, 2027
(3 years from now)
Active
US7754230 Methods and related compositions for reduction of fat 10 Dec, 2027
(3 years from now)
Active
US8298556 Methods and related compositions for the non-surgical removal of fat 03 Aug, 2025
(9 months from now)
Active
US8846066 Methods and related compositions for reduction of fat and skin tightening 08 Feb, 2025
(3 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kybella's drug page


23. Lastacaft

Lastacaft is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8664215 Ocular allergy treatments with alcaftadine 23 Dec, 2027
(3 years from now)
Active
US10617695 Ophthalmic compositions containing alcaftadine 19 Mar, 2027
(2 years from now)
Active
US5468743 Imidazo[2,1-b]benzazepine derivatives, compositions and method of use 21 Nov, 2013
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lastacaft's drug page


24. Latisse

Latisse is protected by 16 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7351404 Method of enhancing hair growth 25 May, 2024
(4 months ago)
Expired
US8101161 Method of enhancing hair growth 25 May, 2024
(4 months ago)
Expired
US8038988 Method of enhancing hair growth 25 Aug, 2023
(1 year, 1 month ago)
Expired
US8263054 Method of enhancing hair growth 25 Aug, 2023
(1 year, 1 month ago)
Expired
US8632760 Method of enhancing hair growth 15 Jan, 2023
(1 year, 8 months ago)
Expired
US8758733 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists 15 Jan, 2023
(1 year, 8 months ago)
Expired
US8926953 Method of enhancing hair growth 15 Jan, 2023
(1 year, 8 months ago)
Expired
US8986715 Method of enhancing hair growth 15 Jan, 2023
(1 year, 8 months ago)
Expired
US9216183 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists 15 Jan, 2023
(1 year, 8 months ago)
Expired
US9226931 Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists 15 Jan, 2023
(1 year, 8 months ago)
Expired
US7388029 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins 21 Jan, 2022
(2 years ago)
Expired
US8541466 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins 31 Jan, 2021
(3 years ago)
Expired
US8906962 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins 31 Jan, 2021
(3 years ago)
Expired
US9579270 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins 31 Jan, 2021
(3 years ago)
Expired
US8017655 Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents 27 Nov, 2012
(11 years ago)
Expired
US6403649 Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents 21 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Latisse's drug page


25. Lexapro

Lexapro is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6916941
(Pediatric)
Crystalline composition containing escitalopram 12 Feb, 2023
(1 year, 8 months ago)
Expired
US7420069
(Pediatric)
Crystalline composition containing escitalopram 12 Feb, 2023
(1 year, 8 months ago)
Expired
US6916941 Crystalline composition containing escitalopram 12 Aug, 2022
(2 years ago)
Expired
US7420069 Crystalline composition containing escitalopram 12 Aug, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lexapro's drug page


26. Linzess

Linzess is protected by 12 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9708371 Treatments for gastrointestinal disorders 16 Aug, 2033
(8 years from now)
Active
US8748573 Formulations comprising linaclotide 30 Oct, 2031
(7 years from now)
Active
US8802628 Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration 30 Oct, 2031
(7 years from now)
Active
US10675325 Stable formulations of linaclotide 11 Aug, 2031
(6 years from now)
Active
US10702576 Stable formulations of linaclotide 11 Aug, 2031
(6 years from now)
Active
US8933030 Treatments for gastrointestinal disorders 17 Feb, 2031
(6 years from now)
Active
US7304036 Methods and compositions for the treatment of gastrointestinal disorders 30 Aug, 2026
(1 year, 10 months from now)
Active
US7371727 Methods and compositions for the treatment of gastrointestinal disorders 28 Jan, 2024
(8 months ago)
Expired
US7704947 Methods and compositions for the treatment of gastrointestinal disorders 28 Jan, 2024
(8 months ago)
Expired
US7745409 Methods and compositions for the treatment of gastrointestinal disorders 28 Jan, 2024
(8 months ago)
Expired
US8080526 Methods and compositions for the treatment of gastrointestinal disorders 28 Jan, 2024
(8 months ago)
Expired
US8110553 Methods and compositions for the treatment of gastrointestinal disorders 28 Jan, 2024
(8 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Linzess's drug page


27. Lumigan

Lumigan is protected by 15 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7851504 Enhanced bimatoprost ophthalmic solution 13 Jun, 2027
(2 years from now)
Active
US8278353 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US8299118 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US8309605 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US8338479 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US8524777 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US8586630 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US8772338 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US8933120 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US8933127 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US9155716 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US9241918 Enhanced bimatoprost ophthalmic solution 16 Mar, 2025
(4 months from now)
Active
US5688819 Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents 19 Aug, 2014
(10 years ago)
Expired
US8017655 Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents 27 Nov, 2012
(11 years ago)
Expired
US6403649 Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents 21 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumigan's drug page


28. Mavik

Mavik is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5744496 Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors 28 Apr, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mavik's drug page


29. Mavyret

Mavyret is protected by 20 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11246866
(Pediatric)
Solid pharmaceutical compositions for treating HCV 24 Dec, 2036
(12 years from now)
Active
US11246866 Solid pharmaceutical compositions for treating HCV 24 Jun, 2036
(11 years from now)
Active
US9321807
(Pediatric)
Crystal forms 05 Dec, 2035
(11 years from now)
Active
USRE48923
(Pediatric)
Crystal forms 08 Nov, 2035
(11 years from now)
Active
US9321807 Crystal forms 05 Jun, 2035
(10 years from now)
Active
USRE48923 Crystal forms 08 May, 2035
(10 years from now)
Active
US10286029
(Pediatric)
Method for treating HCV 14 Sep, 2034
(9 years from now)
Active
US11484534
(Pediatric)
Methods for treating HCV 14 Sep, 2034
(9 years from now)
Active
US10286029 Method for treating HCV 14 Mar, 2034
(9 years from now)
Active
US11484534 Methods for treating HCV 14 Mar, 2034
(9 years from now)
Active
US8937150
(Pediatric)
Anti-viral compounds 18 Nov, 2032
(8 years from now)
Active
US8648037
(Pediatric)
Macrocyclic proline derived HCV serine protease inhibitors 19 Jul, 2032
(7 years from now)
Active
US8937150 Anti-viral compounds 18 May, 2032
(7 years from now)
Active
US8648037 Macrocyclic proline derived HCV serine protease inhibitors 19 Jan, 2032
(7 years from now)
Active
US9586978
(Pediatric)
Anti-viral compounds 06 May, 2031
(6 years from now)
Active
US10028937
(Pediatric)
Anti-viral compounds 10 Dec, 2030
(6 years from now)
Active
US10039754
(Pediatric)
Anti-viral compounds 10 Dec, 2030
(6 years from now)
Active
US9586978 Anti-viral compounds 06 Nov, 2030
(6 years from now)
Active
US10028937 Anti-viral compounds 10 Jun, 2030
(5 years from now)
Active
US10039754 Anti-viral compounds 10 Jun, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mavyret's drug page


30. Namenda

Namenda is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5061703
(Pediatric)
Adamantane derivatives in the prevention and treatment of cerebral ischemia 11 Oct, 2015
(9 years ago)
Expired
US5061703 Adamantane derivatives in the prevention and treatment of cerebral ischemia 11 Apr, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Namenda's drug page


31. Namenda Xr

Namenda Xr is protected by 16 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8039009
(Pediatric)
Modified release formulations of memantine oral dosage forms 24 Sep, 2029
(4 years from now)
Active
US8039009 Modified release formulations of memantine oral dosage forms 24 Mar, 2029
(4 years from now)
Active
US8168209
(Pediatric)
Method and composition for administering an NMDA receptor antagonist to a subject 22 May, 2026
(1 year, 7 months from now)
Active
US8173708
(Pediatric)
Method and composition for administering an NMDA receptor antagonist to a subject 22 May, 2026
(1 year, 7 months from now)
Active
US8283379
(Pediatric)
Methods and compositions for the treatment of CNS-related conditions 22 May, 2026
(1 year, 7 months from now)
Active
US8329752
(Pediatric)
Composition for administering an NMDA receptor antagonist to a subject 22 May, 2026
(1 year, 7 months from now)
Active
US8362085
(Pediatric)
Method for administering an NMDA receptor antagonist to a subject 22 May, 2026
(1 year, 7 months from now)
Active
US8598233
(Pediatric)
Method for administering an NMDA receptor antagonist to a subject 22 May, 2026
(1 year, 7 months from now)
Active
US8168209 Method and composition for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
(1 year, 1 month from now)
Active
US8173708 Method and composition for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
(1 year, 1 month from now)
Active
US8283379 Methods and compositions for the treatment of CNS-related conditions 22 Nov, 2025
(1 year, 1 month from now)
Active
US8329752 Composition for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
(1 year, 1 month from now)
Active
US8362085 Method for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
(1 year, 1 month from now)
Active
US8598233 Method for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
(1 year, 1 month from now)
Active
US5061703
(Pediatric)
Adamantane derivatives in the prevention and treatment of cerebral ischemia 11 Oct, 2015
(9 years ago)
Expired
US5061703 Adamantane derivatives in the prevention and treatment of cerebral ischemia 11 Apr, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Namenda Xr's drug page


32. Namzaric

Namzaric is protected by 21 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8058291 Methods and compositions for the treatment of CNS-related conditions 05 Dec, 2029
(5 years from now)
Active
US8039009
(Pediatric)
Modified release formulations of memantine oral dosage forms 24 Sep, 2029
(4 years from now)
Active
US8039009 Modified release formulations of memantine oral dosage forms 24 Mar, 2029
(4 years from now)
Active
US8168209
(Pediatric)
Method and composition for administering an NMDA receptor antagonist to a subject 22 May, 2026
(1 year, 7 months from now)
Active
US8173708
(Pediatric)
Method and composition for administering an NMDA receptor antagonist to a subject 22 May, 2026
(1 year, 7 months from now)
Active
US8283379
(Pediatric)
Methods and compositions for the treatment of CNS-related conditions 22 May, 2026
(1 year, 7 months from now)
Active
US8329752
(Pediatric)
Composition for administering an NMDA receptor antagonist to a subject 22 May, 2026
(1 year, 7 months from now)
Active
US8362085
(Pediatric)
Method for administering an NMDA receptor antagonist to a subject 22 May, 2026
(1 year, 7 months from now)
Active
US8598233
(Pediatric)
Method for administering an NMDA receptor antagonist to a subject 22 May, 2026
(1 year, 7 months from now)
Active
US8168209 Method and composition for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
(1 year, 1 month from now)
Active
US8173708 Method and composition for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
(1 year, 1 month from now)
Active
US8283379 Methods and compositions for the treatment of CNS-related conditions 22 Nov, 2025
(1 year, 1 month from now)
Active
US8293794 Methods and compositions for the treatment of CNS-related conditions 22 Nov, 2025
(1 year, 1 month from now)
Active
US8329752 Composition for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
(1 year, 1 month from now)
Active
US8338485 Compositions for the treatment of CNS-related conditions 22 Nov, 2025
(1 year, 1 month from now)
Active
US8338486 Methods for the treatment of CNS-related conditions 22 Nov, 2025
(1 year, 1 month from now)
Active
US8362085 Method for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
(1 year, 1 month from now)
Active
US8580858 Compositions for the treatment of CNS-related conditions 22 Nov, 2025
(1 year, 1 month from now)
Active
US8598233 Method for administering an NMDA receptor antagonist to a subject 22 Nov, 2025
(1 year, 1 month from now)
Active
US5061703
(Pediatric)
Adamantane derivatives in the prevention and treatment of cerebral ischemia 11 Oct, 2015
(9 years ago)
Expired
US5061703 Adamantane derivatives in the prevention and treatment of cerebral ischemia 11 Apr, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Namzaric's drug page


33. Niaspan

Niaspan is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6469035 Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid 15 Mar, 2018
(6 years ago)
Expired
US6080428 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 27 May, 2017
(7 years ago)
Expired
US6818229 Intermediate release nicotinic acid compositions for treating hyperlipidemia 15 Feb, 2014
(10 years ago)
Expired
US6129930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night 20 Sep, 2013
(11 years ago)
Expired
US6406715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles 20 Sep, 2013
(11 years ago)
Expired
US6676967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia 20 Sep, 2013
(11 years ago)
Expired
US6746691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics 20 Sep, 2013
(11 years ago)
Expired
US6818229 Intermediate release nicotinic acid compositions for treating hyperlipidemia 20 Sep, 2013
(11 years ago)
Expired
US7011848 Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor 20 Sep, 2013
(11 years ago)
Expired
US7998506 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 20 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Niaspan's drug page


34. Niaspan Titration Starter Pack

Niaspan Titration Starter Pack is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6080428 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 27 May, 2017
(7 years ago)
Expired
US6129930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night 20 Sep, 2013
(11 years ago)
Expired
US6406715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles 20 Sep, 2013
(11 years ago)
Expired
US6746691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics 20 Sep, 2013
(11 years ago)
Expired
US7011848 Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor 20 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Niaspan Titration Starter Pack's drug page


35. Nimbex

Nimbex is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5453510 Neuromuscular blocking agents 26 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nimbex's drug page


36. Nimbex Preservative Free

Nimbex Preservative Free is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5453510 Neuromuscular blocking agents 26 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nimbex Preservative Free's drug page


37. Norvir

Norvir is protected by 34 patents, out of which 29 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8470347
(Pediatric)
Self-emulsifying active substance formulation and use of this formulation 17 Mar, 2027
(2 years from now)
Active
US8470347 Self-emulsifying active substance formulation and use of this formulation 17 Sep, 2026
(1 year, 11 months from now)
Active
US8268349
(Pediatric)
Solid pharmaceutical dosage form 25 Feb, 2025
(4 months from now)
Active
US8399015
(Pediatric)
Solid pharmaceutical dosage form 25 Feb, 2025
(4 months from now)
Active
US8691878
(Pediatric)
Solid pharmaceutical dosage form 25 Feb, 2025
(4 months from now)
Active
US8268349 Solid pharmaceutical dosage form 25 Aug, 2024
(a month ago)
Expired
US8399015 Solid pharmaceutical dosage form 25 Aug, 2024
(a month ago)
Expired
US8691878 Solid pharmaceutical dosage form 25 Aug, 2024
(a month ago)
Expired
US7364752
(Pediatric)
Solid dispersion pharamaceutical formulations 10 May, 2021
(3 years ago)
Expired
US7141593
(Pediatric)
Pharmaceutical formulations 22 Nov, 2020
(3 years ago)
Expired
US7432294
(Pediatric)
Pharmaceutical formulations 22 Nov, 2020
(3 years ago)
Expired
US7364752 Solid dispersion pharamaceutical formulations 10 Nov, 2020
(3 years ago)
Expired
US7141593 Pharmaceutical formulations 22 May, 2020
(4 years ago)
Expired
US7432294 Pharmaceutical formulations 22 May, 2020
(4 years ago)
Expired
US7148359
(Pediatric)
Polymorph of a pharmaceutical 19 Jan, 2020
(4 years ago)
Expired
US7148359 Polymorph of a pharmaceutical 19 Jul, 2019
(5 years ago)
Expired
US6232333
(Pediatric)
Pharmaceutical composition 07 May, 2018
(6 years ago)
Expired
US6232333 Pharmaceutical composition 07 Nov, 2017
(6 years ago)
Expired
US6037157
(Pediatric)
Method for improving pharmacokinetics 26 Dec, 2016
(7 years ago)
Expired
US6703403
(Pediatric)
Method for improving pharmacokinetics 26 Dec, 2016
(7 years ago)
Expired
US6037157 Method for improving pharmacokinetics 26 Jun, 2016
(8 years ago)
Expired
US6703403 Method for improving pharmacokinetics 26 Jun, 2016
(8 years ago)
Expired
US5648497
(Pediatric)
Retroviral protease inhibiting compounds 15 Jan, 2015
(9 years ago)
Expired
US5484801
(Pediatric)
Pharmaceutical composition for inhibiting HIV protease 28 Jul, 2014
(10 years ago)
Expired
US5648497 Retroviral protease inhibiting compounds 15 Jul, 2014
(10 years ago)
Expired
US5948436
(Pediatric)
Pharmaceutical composition 13 Mar, 2014
(10 years ago)
Expired
US5541206
(Pediatric)
Retroviral protease inhibiting compounds 30 Jan, 2014
(10 years ago)
Expired
US5635523
(Pediatric)
Retroviral protease inhibiting compounds 30 Jan, 2014
(10 years ago)
Expired
US5674882
(Pediatric)
Retroviral protease inhibiting compounds 30 Jan, 2014
(10 years ago)
Expired
US5484801 Pharmaceutical composition for inhibiting HIV protease 28 Jan, 2014
(10 years ago)
Expired
US5948436 Pharmaceutical composition 13 Sep, 2013
(11 years ago)
Expired
US5541206 Retroviral protease inhibiting compounds 30 Jul, 2013
(11 years ago)
Expired
US5635523 Retroviral protease inhibiting compounds 30 Jul, 2013
(11 years ago)
Expired
US5674882 Retroviral protease inhibiting compounds 30 Jul, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norvir's drug page


38. Oriahnn (copackaged)

Oriahnn (copackaged) is protected by 11 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11690845 Methods of administering elagolix 27 Aug, 2040
(15 years from now)
Active
US11542239 Elagolix sodium compositions and processes 23 Jul, 2039
(14 years from now)
Active
US12083227 Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis 20 Aug, 2038
(13 years from now)
Active
US10881659 Methods of treating heavy menstrual bleeding 14 Mar, 2034
(9 years from now)
Active
US11045470 Methods of treating heavy menstrual bleeding 14 Mar, 2034
(9 years from now)
Active
US7419983 Gonadotropin-releasing hormone receptor antagonists and methods related thereto 06 Jul, 2029
(4 years from now)
Active
US11459305 Processes for the preparation of uracil derivatives 07 Nov, 2028
(4 years from now)
Active
US7056927 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 10 Sep, 2024
(a month ago)
Expired
US7179815 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 07 Mar, 2021
(3 years ago)
Expired
US6872728 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 25 Jan, 2021
(3 years ago)
Expired
US7462625 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 25 Jan, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oriahnn (copackaged)'s drug page


39. Orilissa

Orilissa is protected by 13 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11690845 Methods of administering elagolix 27 Aug, 2040
(15 years from now)
Active
US11542239 Elagolix sodium compositions and processes 23 Jul, 2039
(14 years from now)
Active
US11690854 Methods of treating heavy menstrual bleeding 19 Apr, 2038
(13 years from now)
Active
US10537572 Methods of administering elagolix 01 Sep, 2036
(11 years from now)
Active
US10682351 Methods of administering elagolix 01 Sep, 2036
(11 years from now)
Active
US11344551 Methods of treating heavy menstrual bleeding 14 Mar, 2034
(9 years from now)
Active
US11707464 Methods of treating heavy menstrual bleeding 14 Mar, 2034
(9 years from now)
Active
US7419983 Gonadotropin-releasing hormone receptor antagonists and methods related thereto 06 Jul, 2029
(4 years from now)
Active
US7056927 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 10 Sep, 2024
(a month ago)
Expired
US7176211 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 06 Jul, 2024
(3 months ago)
Expired
US7179815 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 07 Mar, 2021
(3 years ago)
Expired
US6872728 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 25 Jan, 2021
(3 years ago)
Expired
US7462625 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto 25 Jan, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orilissa's drug page


40. Oxytrol For Women

Oxytrol For Women is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6743441 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy 26 Apr, 2020
(4 years ago)
Expired
US7081249 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy 26 Apr, 2020
(4 years ago)
Expired
US7081250 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy 26 Apr, 2020
(4 years ago)
Expired
US7081251 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy 26 Apr, 2020
(4 years ago)
Expired
US7081252 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy 26 Apr, 2020
(4 years ago)
Expired
US7179483 Compositions and methods for transdermal oxybutynin therapy 26 Apr, 2020
(4 years ago)
Expired
US5601839 Triacetin as a penetration enhancer for transdermal delivery of a basic drug 26 Apr, 2015
(9 years ago)
Expired
US5834010 Triacetin as a penetration enhancer for transdermal delivery of a basic drug 26 Apr, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxytrol For Women's drug page


41. Ozurdex

Ozurdex is protected by 17 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6899717 Methods and apparatus for delivery of ocular implants 01 Nov, 2023
(11 months ago)
Expired
US10076526 Ocular implant made by a double extrusion process 09 Jan, 2023
(1 year, 9 months ago)
Expired
US10702539 Ocular implant made by a double extrusion process 09 Jan, 2023
(1 year, 9 months ago)
Expired
US8034366 Ocular implant made by a double extrusion process 09 Jan, 2023
(1 year, 9 months ago)
Expired
US8034370 Ocular implant made by a double extrusion process 09 Jan, 2023
(1 year, 9 months ago)
Expired
US8506987 Ocular implant made by a double extrusion process 09 Jan, 2023
(1 year, 9 months ago)
Expired
US9192511 Ocular implant made by a double extrusion process 09 Jan, 2023
(1 year, 9 months ago)
Expired
US7767223 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use 28 Nov, 2021
(2 years ago)
Expired
US6726918 Methods for treating inflammation-mediated conditions of the eye 20 Oct, 2020
(3 years ago)
Expired
US7033605 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor 20 Oct, 2020
(3 years ago)
Expired
US8043628 Methods for reducing edema 20 Oct, 2020
(3 years ago)
Expired
US8063031 Implants and methods for treating inflammation-mediated conditions of the eye 20 Oct, 2020
(3 years ago)
Expired
US8088407 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor 20 Oct, 2020
(3 years ago)
Expired
US9012437 Implants and methods for treating inflammation-mediated conditions of the eye 20 Oct, 2020
(3 years ago)
Expired
US9283178 Methods for treating edema in the eye and intraocular implants for use therefor 20 Oct, 2020
(3 years ago)
Expired
US9592242 Methods for treating edema in the eye and intraocular implants for use therefor 20 Oct, 2020
(3 years ago)
Expired
US9775849 Implants and methods for treating inflammation-mediated conditions of the eye 20 Oct, 2020
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ozurdex's drug page


42. Qulipta

Qulipta is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10117836 Tablet formulation for CGRP active compounds 30 Jan, 2035
(10 years from now)
Active
US9850246 Process for making CGRP receptor antagonists 13 Mar, 2033
(8 years from now)
Active
US8754096 Piperidinone carboxamide azaindane CGRP receptor antagonists 19 Jul, 2032
(7 years from now)
Active
US9499545 Piperidinone carboxamide azaindane CGRP receptor antagonists 10 Nov, 2031
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qulipta's drug page


43. Rectiv

Rectiv is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7189761 Nitric oxide donor composition and method for treatment of anal disorders 27 May, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rectiv's drug page


44. Restasis

Restasis is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8629111 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US8633162 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US8642556 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US8648048 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US8685930 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US9248191 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US5474979 Nonirritating emulsions for sensitive tissue 17 May, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Restasis's drug page


45. Restasis Multidose

Restasis Multidose is protected by 10 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9669974 Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids 11 May, 2034
(9 years from now)
Active
US9676525 Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids 07 Feb, 2034
(9 years from now)
Active
US8561859 Dispensing device 16 Apr, 2032
(7 years from now)
Active
US8292129 Dispensing device 25 Feb, 2031
(6 years from now)
Active
US8629111 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US8633162 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US8642556 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US8648048 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US8685930 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired
US9248191 Methods of providing therapeutic effects using cyclosporin components 27 Aug, 2024
(a month ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Restasis Multidose's drug page


46. Rinvoq

Rinvoq is protected by 37 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11564922 Methods of treating crohn's disease and ulcerative colitis 09 Mar, 2038
(13 years from now)
Active
US11607411 Methods of treating Crohn's disease and ulcerative colitis 09 Mar, 2038
(13 years from now)
Active
US10202393 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US10344036 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US10519164 Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US10550126 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US10597400 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US10730883 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US10981923 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US10981924 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US10995095 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11186584 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11198697 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11365198 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11512092 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11524964 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11535624 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11535625 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11535626 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11661425 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11680069 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11718627 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11767326 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11773105 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11773106 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11780847 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11780848 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11787815 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11795175 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11976077 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof 17 Oct, 2036
(12 years from now)
Active
US11993605 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11993606 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US12077545 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US9951080 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US9963459 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
USRE47221 Tricyclic compounds 16 Aug, 2033
(8 years from now)
Active
US8962629 Tricyclic compounds 15 Jan, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rinvoq's drug page


47. Rinvoq Lq

Rinvoq Lq is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10981923 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11186584 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11661425 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11680069 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11718627 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US11773105 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
US9951080 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 17 Oct, 2036
(12 years from now)
Active
USRE47221 Tricyclic compounds 16 Aug, 2033
(8 years from now)
Active
US8962629 Tricyclic compounds 15 Jan, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rinvoq Lq's drug page


48. Savella

Savella is protected by 4 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7994220 Milnacipran for the long-term treatment of fibromyalgia syndrome 19 Sep, 2029
(4 years from now)
Active
US6602911 Methods of treating fibromyalgia 14 Jan, 2023
(1 year, 8 months ago)
Expired
US6992110 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain 05 Nov, 2021
(2 years ago)
Expired
US7888342 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain 05 Nov, 2021
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Savella's drug page


49. Simcor

Simcor is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6469035 Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid 15 Mar, 2018
(6 years ago)
Expired
US6080428 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 27 May, 2017
(7 years ago)
Expired
US6129930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night 20 Sep, 2013
(11 years ago)
Expired
US6406715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles 20 Sep, 2013
(11 years ago)
Expired
US6676967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia 20 Sep, 2013
(11 years ago)
Expired
US6746691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics 20 Sep, 2013
(11 years ago)
Expired
US6818229 Intermediate release nicotinic acid compositions for treating hyperlipidemia 20 Sep, 2013
(11 years ago)
Expired
US7011848 Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor 20 Sep, 2013
(11 years ago)
Expired
US7998506 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor 20 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Simcor's drug page


50. Tarka

Tarka is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5721244 Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs 24 Feb, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tarka's drug page


51. Technivie

Technivie is protected by 19 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8691938 Anti-viral compounds 13 Apr, 2032
(7 years from now)
Active
US8420596
(Pediatric)
Macrocyclic hepatitis C serine protease inhibitors 10 Oct, 2031
(6 years from now)
Active
US8686026 Solid compositions 09 Jun, 2031
(6 years from now)
Active
US8420596 Macrocyclic hepatitis C serine protease inhibitors 10 Apr, 2031
(6 years from now)
Active
US9044480 Compositions and methods for treating HCV 10 Apr, 2031
(6 years from now)
Active
US9006387 Anti-viral compounds 10 Jun, 2030
(5 years from now)
Active
US8642538 Macrocyclic hepatitis C serine protease inhibitors 10 Sep, 2029
(4 years from now)
Active
US8268349
(Pediatric)
Solid pharmaceutical dosage form 25 Feb, 2025
(4 months from now)
Active
US8399015
(Pediatric)
Solid pharmaceutical dosage form 25 Feb, 2025
(4 months from now)
Active
US8268349 Solid pharmaceutical dosage form 25 Aug, 2024
(a month ago)
Expired
US8399015 Solid pharmaceutical dosage form 25 Aug, 2024
(a month ago)
Expired
US7364752
(Pediatric)
Solid dispersion pharamaceutical formulations 10 May, 2021
(3 years ago)
Expired
US7364752 Solid dispersion pharamaceutical formulations 10 Nov, 2020
(3 years ago)
Expired
US7148359
(Pediatric)
Polymorph of a pharmaceutical 19 Jan, 2020
(4 years ago)
Expired
US7148359 Polymorph of a pharmaceutical 19 Jul, 2019
(5 years ago)
Expired
US6037157
(Pediatric)
Method for improving pharmacokinetics 26 Dec, 2016
(7 years ago)
Expired
US6703403
(Pediatric)
Method for improving pharmacokinetics 26 Dec, 2016
(7 years ago)
Expired
US6037157 Method for improving pharmacokinetics 26 Jun, 2016
(8 years ago)
Expired
US6703403 Method for improving pharmacokinetics 26 Jun, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Technivie's drug page


52. Teflaro

Teflaro is protected by 5 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8247400 Cephem compounds useful for the treatment of bacterial infections 10 Feb, 2031
(6 years from now)
Active
US9629861 Compositions and methods for treating bacterial infections using ceftaroline 21 Sep, 2030
(5 years from now)
Active
US6906055 Phosphonocephem compound 15 Dec, 2021
(2 years ago)
Expired
US7419973 Phosphonocephem compound 15 Dec, 2021
(2 years ago)
Expired
US6417175 Phosphonocephem derivatives, process for the preparation of the same, and use thereof 17 Dec, 2018
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Teflaro's drug page


53. Teveten

Teveten is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5656650 Angiotensin II receptor blocking compositions 12 Aug, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Teveten's drug page


54. Teveten Hct

Teveten Hct is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5656650 Angiotensin II receptor blocking compositions 12 Aug, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Teveten Hct's drug page


55. Tricor

Tricor is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7276249 Nanoparticulate fibrate formulations 21 Feb, 2023
(1 year, 7 months ago)
Expired
US7320802 Methods of treatment using nanoparticulate fenofibrate compositions 21 Feb, 2023
(1 year, 7 months ago)
Expired
US6375986 Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate 21 Sep, 2020
(4 years ago)
Expired
US6074670 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it 09 Jan, 2018
(6 years ago)
Expired
US6277405 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it 09 Jan, 2018
(6 years ago)
Expired
US6589552 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it 09 Jan, 2018
(6 years ago)
Expired
US6652881 Fenofibrate pharmaceutical composition having high bioavailability 09 Jan, 2018
(6 years ago)
Expired
US7037529 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it 09 Jan, 2018
(6 years ago)
Expired
US7041319 Fenofibrate pharmaceutical composition having high bioavailabilty 09 Jan, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tricor's drug page


56. Trilipix

Trilipix is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7259186 Salts of fenofibric acid and pharmaceutical formulations thereof 07 Jan, 2025
(2 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trilipix's drug page


57. Ubrelvy

Ubrelvy is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11717515 Treatment of migraine 22 Dec, 2041
(17 years from now)
Active
US11857542 Treatment of migraine 22 Dec, 2041
(17 years from now)
Active
US12070450 Treatment of migraine 22 Dec, 2041
(17 years from now)
Active
US10117836 Tablet formulation for CGRP active compounds 30 Jan, 2035
(10 years from now)
Active
US11925709 Tablet formulation for CGRP active compounds 30 Jan, 2035
(10 years from now)
Active
US8912210 Piperidinone carboxamide azaindane CGRP receptor antagonists 23 Dec, 2033
(9 years from now)
Active
US8754096 Piperidinone carboxamide azaindane CGRP receptor antagonists 19 Jul, 2032
(7 years from now)
Active
US9499545 Piperidinone carboxamide azaindane CGRP receptor antagonists 10 Nov, 2031
(7 years from now)
Active
US9833448 Piperidinone carboxamide azaindane CGRP receptor antagonists 10 Nov, 2031
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ubrelvy's drug page


58. Ultane

Ultane is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6074668
(Pediatric)
Container for an inhalation anesthetic 09 Jul, 2018
(6 years ago)
Expired
US6074668 Container for an inhalation anesthetic 09 Jan, 2018
(6 years ago)
Expired
US5990176
(Pediatric)
Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jul, 2017
(7 years ago)
Expired
US6288127
(Pediatric)
Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jul, 2017
(7 years ago)
Expired
US6444859
(Pediatric)
Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jul, 2017
(7 years ago)
Expired
US5990176 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jan, 2017
(7 years ago)
Expired
US6288127 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jan, 2017
(7 years ago)
Expired
US6444859 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid 27 Jan, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ultane's drug page


59. Venclexta

Venclexta is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10993942 Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor 06 Sep, 2033
(8 years from now)
Active
US11110087 Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor 06 Sep, 2033
(8 years from now)
Active
US11413282 Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor 06 Sep, 2033
(8 years from now)
Active
US11590128 Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor 06 Sep, 2033
(8 years from now)
Active
US9539251 Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor 06 Sep, 2033
(8 years from now)
Active
US11369599 Melt-extruded solid dispersions containing an apoptosis-inducing agent 23 May, 2032
(7 years from now)
Active
US8722657 Salts and crystalline forms of an apoptosis-inducing agent 29 Jan, 2032
(7 years from now)
Active
US10730873 Salts and crystalline forms of an apoptosis-inducing agent 21 Nov, 2031
(7 years from now)
Active
US8546399 Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases 27 Jun, 2031
(6 years from now)
Active
US9174982 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases 26 May, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Venclexta's drug page


60. Viberzi

Viberzi is protected by 20 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10188632 Opioid receptor modulator dosage formulations 14 Mar, 2033
(8 years from now)
Active
US11007179 Opioid receptor modulator dosage formulations 14 Mar, 2033
(8 years from now)
Active
US11090291 Opioid receptor modulator dosage formulations 14 Mar, 2033
(8 years from now)
Active
US11160792 Opioid receptor modulator dosage formulations 14 Mar, 2033
(8 years from now)
Active
US11229627 Opioid receptor modulator dosage formulations 14 Mar, 2033
(8 years from now)
Active
US11311516 Opioid receptor modulator dosage formulations 14 Mar, 2033
(8 years from now)
Active
US11484527 Opioid receptor modulator dosage formulations 14 Mar, 2033
(8 years from now)
Active
US9675587 Opioid receptor modulator dosage formulations 14 Mar, 2033
(8 years from now)
Active
US7741356 Compounds as opioid receptor modulators 27 May, 2029
(4 years from now)
Active
US8691860 Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid 07 Jul, 2028
(3 years from now)
Active
US9115091 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid 07 Jul, 2028
(3 years from now)
Active
US9364489 Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid 07 Jul, 2028
(3 years from now)
Active
US9789125 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid 07 Jul, 2028
(3 years from now)
Active
US10213415 Compounds as opioid receptor modulators 14 Mar, 2025
(4 months from now)
Active
US7786158 Compounds as opioid receptor modulators 14 Mar, 2025
(4 months from now)
Active
US8344011 Compounds as opioid receptor modulators 14 Mar, 2025
(4 months from now)
Active
US8609709 Compounds as opioid receptor modulators 14 Mar, 2025
(4 months from now)
Active
US8772325 Compounds as opioid receptor modulators 14 Mar, 2025
(4 months from now)
Active
US9205076 Compounds as opioid receptor modulators 14 Mar, 2025
(4 months from now)
Active
US9700542 Compounds as opioid receptor modulators 14 Mar, 2025
(4 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viberzi's drug page


61. Vicoprofen

Vicoprofen is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6348216 Ibuprofen and narcotic analgesic compositions 10 Jun, 2017
(7 years ago)
Expired
US6599531 Method of making ibuprofen and narcotic analgesic compositions 10 Jun, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vicoprofen's drug page


62. Viekira Pak (copackaged)

Viekira Pak (copackaged) is protected by 21 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10201542 Formulations of pyrimidinedione derivative compounds 18 Oct, 2033
(9 years from now)
Active
US9629841 Formulations of pyrimidinedione derivative compounds 18 Oct, 2033
(9 years from now)
Active
US8466159 Methods for treating HCV 04 Sep, 2032
(7 years from now)
Active
US8492386 Methods for treating HCV 04 Sep, 2032
(7 years from now)
Active
US8680106 Methods for treating HCV 04 Sep, 2032
(7 years from now)
Active
US8685984 Methods for treating HCV 04 Sep, 2032
(7 years from now)
Active
US8691938 Anti-viral compounds 13 Apr, 2032
(7 years from now)
Active
US8686026 Solid compositions 09 Jun, 2031
(6 years from now)
Active
US8420596 Macrocyclic hepatitis C serine protease inhibitors 10 Apr, 2031
(6 years from now)
Active
US9044480 Compositions and methods for treating HCV 10 Apr, 2031
(6 years from now)
Active
US9006387 Anti-viral compounds 10 Jun, 2030
(5 years from now)
Active
US8642538 Macrocyclic hepatitis C serine protease inhibitors 10 Sep, 2029
(4 years from now)
Active
US8188104 Anti-infective agents and uses thereof 17 May, 2029
(4 years from now)
Active
US8501238 Anti-infective agents and uses thereof 19 Dec, 2028
(4 years from now)
Active
US9139536 Anti-infective agents and uses thereof 09 Nov, 2028
(4 years from now)
Active
US8268349 Solid pharmaceutical dosage form 25 Aug, 2024
(a month ago)
Expired
US8399015 Solid pharmaceutical dosage form 25 Aug, 2024
(a month ago)
Expired
US7364752 Solid dispersion pharamaceutical formulations 10 Nov, 2020
(3 years ago)
Expired
US7148359 Polymorph of a pharmaceutical 19 Jul, 2019
(5 years ago)
Expired
US6037157 Method for improving pharmacokinetics 26 Jun, 2016
(8 years ago)
Expired
US6703403 Method for improving pharmacokinetics 26 Jun, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viekira Pak (copackaged)'s drug page


63. Viekira Xr

Viekira Xr is protected by 22 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10105365 Solid antiviral dosage forms 02 Jan, 2035
(10 years from now)
Active
US9333204 Solid antiviral dosage forms 02 Jan, 2035
(10 years from now)
Active
US9744170 Solid antiviral dosage forms 02 Jan, 2035
(10 years from now)
Active
US8466159 Methods for treating HCV 04 Sep, 2032
(7 years from now)
Active
US8492386 Methods for treating HCV 04 Sep, 2032
(7 years from now)
Active
US8680106 Methods for treating HCV 04 Sep, 2032
(7 years from now)
Active
US8685984 Methods for treating HCV 04 Sep, 2032
(7 years from now)
Active
US10201541 Compositions and methods for treating HCV 17 May, 2032
(7 years from now)
Active